News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SKB BIO (06990.HK) SKB118 New Drug IND Application Approved in Mainland China
SKB BIO-B (06990.HK) announced that it has received a Clinical Trial Notice from the Center for Drug Evaluation of the National Medical Products Administration, approving the Inves...
Reset
Send
The window will close in 5 seconds
SKB BIO (06990.HK) SKB118 New Drug IND Application Approved in Mainland China
Close
Recommend
1
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

SKB BIO-B (06990.HK)  -11.600 (-2.517%)    Short selling $25.99M; Ratio 32.911%   announced that it has received a Clinical Trial Notice from the Center for Drug Evaluation of the National Medical Products Administration, approving the Investigational New Drug (IND) application for its programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody SKB118 (also known as CR-001). The drug is intended for the treatment of advanced solid tumors. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 12:25.)

Related News JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO (01801.HK), WUXI APPTEC (02359.HK), WUXI XDC (02268.HK), SKB BIO (06990.HK)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.